August 15, 2022 8:06am

As I wrote Friday night, “The question is … investors might feel good this week but, how long will uptrend last as the trend has not been a friend forever?”

Earnings: Brainstorm Cell Therapeutics

Pre-open indications:  x Sell into Strength, x Negative Indications, and 1 Puff/Pump/Promote

RMi outlines a daily bell ringing of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

I DEVOTE a HUGE amount of time to “reckoning” the geography of my coverage group - it’s more than opinion, I deal in the facts and numbers that back them up.

The 8:00 A.M., ET edition

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.


Dow futures are DOWN -0.52% or (-177 points), S&P futures are DOWN -0.55% (-24 points) and NASDAQ futures are DOWN -0.39% (-53 points) early in the pre-open – so far,


U.S. equity futures were lower Monday,

European markets were only inching higher

Asia-Pacific markets were mostly higher while Chinese markets were mixed.



Indexes rose sharply on Friday, clinching the fourth (4th) straight positive week for the S&P 500.

The Dow closed UP +424.38 points (+1.27%); the S&P closed UP +72.88 points (-+1.73%) while the Nasdaq closed UP +267.27 points (+2.09%)

The Dow was up +2.92%, the S&P 500 +3.25% on the week while the Nasdaq moved higher by 3.08%; the fourth (4th) positive week in a row.

Monday’s moves come after disappointing economic data out of China overnight. The country’s central bank also cut rates unexpectedly, raising concern over China’s economic recovery.


RegMed Investors’ (RMi) closing bell: “sector extends gains while I said take profits. The question is … investors might feel good this week but, how long will uptrend last as the trend has not been a friend forever?


Ebb and flow –

Q3/22 – August – 6 positive and 4 negative close

July -1 holiday, 10 negative and 10 positive closes

Q2/22 –

June – 1 holiday, 9 positive and 11 negative closes

·         May - 11 positive and 10 negative closes

·         April - 1 holiday, 6 positive and 13 negative closes


·         March – 13 negative and 10 positive closes

·         February stats: 11 negative, 8 positive closes and 1 holiday

·         January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes


Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

Negative Indication:

Regenxbio (RGNX) closed up +$0.12 to $33.37 after Thursday’s down -$1.54 with a negative -$0.12 or -0.36% pre-open indication,

BioLife Solutions (BLFS) closed up +$0.99 to $24.59 after Thursday’s -$0.57, Wednesday’s +$3.82 and Tuesday’s -$0.91 with a negative -$0.74 or -3.01% pre-open indication.

CRISPR Therapeutics (CRSP) closed up +$1.20 to $78.66 after Thursday’s -$1.41, Wednesday’s +$3.74 after Tuesday’s -$6.26 with a negative -$0.16 or -0.20% pre-open indication,

Positive Indication:

uniQure NV (QURE)closed up +$0.69 to $20.38 after Thursday’s +$0.16 to $19.69 and Wednesday’s +$0.51 with a positive =$0.44 or +2.16% pre-open indication.

Chinook Therapeutics (KDNY) closed up +$0.65 to $20.65 with a positive +$4.55% pre-open indication.

Maintain Sell into Strength:

Verve Therapeutics (VERV) closed up again +$1.80 to $35.50 after Thursday’s +$1.86, Wednesday’s +$3.59, Tuesday’s +$1.17 and Monday’s +$0.50 with a negative -$1.04 or -2.92% pre-open indication,


Puff/Pump and Promote: Maintaining SELL

Biostage (OTCQB: BSTG) closed flat again on Friday following Thursday and after Wednesday’s $0.00 after Tuesday’s -$0.45 to $4.55 after being flat on Monday with 92 shares traded after last Friday’s flat <3 mo. Average = 935 shares>

·         Its BOD approved on 7/28 amending and restating their Certificate of Incorporation to affect a reverse split of the issued and outstanding common stock at a ratio of not less than 1-for-1.25 and not greater than 1-for-5. What about all those PPM (private placements) as an offering follows?

·         BSTG seems to have the ONLY avenue to finance to utilize non-U.S. Chinese investors? Are we in favor of Beijing funding and continue to control BSTG in our own country? Another question, makes one wonder, Newbridge Securities?

·         How much lipstick is a lot on this pig with an almost 4-year-old IND and NO clinical trial initiation?

·         New CFO, number #7 for the chute?

·         WATCH and be ready for a BIG reverse of shares to enable offering from multiple private placements as it tries to facilitate an offering with Newbridge Securities?


The BOTTOM LINE: I try to keep it simple … and short!

Since investors don’t know what share pricings are going to be like in the future, chances are pretty good that they’ll just behave the way we’ve experienced so far this year

This week: Brainstorm Cell Therapeutics on 8/15, Monday … to date.

As I have written, “It’s STILL nice to be RIGHT” about the direction of the sector having “DEVOTED a HUGE amount of time to “reckoning” the geography of my coverage group.”

Whether information or intelligence is good, bad or somewhere in between; RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

More than a little slow this a.m.

A bit of a difficulty today from yesterday, had to get walking stick out for use - back injury; not 35 anymore as 50 lb. leaf blower and heavy yard work times are now - OVER <a favorite> and headed to chiropractor.


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.